News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Scolds Teva Pharmaceutical Industries Limited (TEVA) for an Unbalanced and Overblown Handout


4/23/2013 7:36:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

File this under ‘how could they not know?’ Drugmakers are well aware of the requirements for readying promotional materials, steps that include submitting a form to spell out the messages to be conveyed. Teva Pharmaceuticals, however, was tagged earlier this month by the FDA for preparing a physician handout for its Clozapine schizophrenia medication that was sorely lacking – risks were minimized and various unsubstantiated claims were made. In an April 8 untitled letter, the FDA took the drugmaker to task because the article implied Clozapine demonstrated significant efficacy in treating four of five symptom clusters – excitement, positive, cognitive, and depression/anxiety, as well as specific symptoms of excitement - as well as superiority to other meds.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaLive

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES